Zilucoplan (Zilbrysq)

FDA-approved context Immune Support 2 sources

Zilucoplan is a synthetic, macrocyclic peptide that binds to complement component 5 (C5) and inhibits its cleavage. It is FDA-approved under the brand name Zilbrysq for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive, offering a targeted approach to reduce immune-mediated muscle weakness.

01Dosing reference

Amount

Dose based on body weight (e.g., 16.6 mg, 23 mg, or 32.4 mg)

Frequency

Once daily

Cycle

Continuous daily use as prescribed

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

C5 Binding

Zilucoplan specifically binds to complement component 5 (C5) in the immune system.

Cleavage Inhibition

It prevents the cleavage of C5 into its active fragments, C5a and C5b.

MAC Formation Prevention

By blocking C5b generation, it prevents the downstream assembly of the membrane attack complex (MAC), reducing immune-mediated damage at the neuromuscular junction.

03Human evidence

Significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to placebo.

Phase 3 RAISE trial involving adult patients with AChR antibody-positive generalized myasthenia gravis.

Rapid onset of action with sustained efficacy and a manageable safety profile over 12 weeks.

Clinical trials evaluating daily subcutaneous administration in gMG patients.

04Preclinical evidence

Effective inhibition of complement-mediated red blood cell lysis.

In vitro hemolytic assays demonstrating potent C5 inhibition.

Prevention of neuromuscular junction damage in animal models of myasthenia gravis.

Preclinical in vivo models assessing the protective effects of C5 blockade.

05What is known vs. unknown

Reasonably established

FDA-approved for generalized myasthenia gravis in AChR antibody-positive adults.
Administered as a once-daily subcutaneous injection.
Functions as a targeted complement C5 inhibitor.
Carries a Boxed Warning for serious meningococcal infections.

Unknowns & limits

Long-term safety and efficacy beyond the duration of current clinical trials are still being monitored.
Efficacy in patients who are AChR antibody-negative remains unestablished.
Requires strict adherence to vaccination protocols against Neisseria meningitidis due to infection risks.

06Safety & regulatory context

Regulatory statusZilucoplan (Zilbrysq) is FDA-approved for adult patients with AChR antibody-positive generalized myasthenia gravis. Due to its mechanism of inhibiting the complement system, it carries a Boxed Warning for an increased risk of serious and life-threatening meningococcal infections. Patients must be vaccinated against Neisseria meningitidis prior to starting therapy. Common side effects include injection site reactions, upper respiratory tract infections, and diarrhea. It is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

07Compared with Eculizumab (Soliris)

Zilucoplan (Zilbrysq) vs. Eculizumab (Soliris)

Key difference

Zilucoplan is a small macrocyclic peptide administered via daily subcutaneous injection, whereas Eculizumab is a monoclonal antibody administered via intravenous infusion.

When researchers discuss each

Researchers discuss Zilucoplan when focusing on self-administered, peptide-based C5 inhibitors, and Eculizumab when discussing established, infusion-based monoclonal antibody therapies for complement-mediated diseases.

08Glossary

Complement Component 5 (C5)

A protein of the immune system that plays a key role in the complement cascade, leading to inflammation and cell damage when activated.

Membrane Attack Complex (MAC)

A structure formed on the surface of pathogenic cells (or host cells in autoimmune diseases) as a result of complement system activation, causing cell lysis.

Myasthenia Gravis (MG)

A chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.

09Knowledge check

Q1What is the primary mechanism of action of Zilucoplan?

Q2What serious infection risk carries a Boxed Warning for Zilucoplan?

Q3Which limitation of the clinical evidence for Zilucoplan is explicitly stated in the dossier?

Q4According to the dossier, in what research context is Zilucoplan most likely to be discussed compared with Eculizumab?

Q5Which regulatory or safety program is mentioned in the dossier as applying to Zilucoplan?

10Sources

More in Immune Support

See all

Thymosin Alpha-1

Immune Support

Human clinical

Thymosin Alpha-1 is a naturally occurring peptide produced by the thymus gland that plays a vital role in modulating the immune system. Research demonstrates its ability to enhance T-cell function, improve vaccine response, and support the body's defense against viral infections and certain cancers.

1.5 mg

LL-37

Immune Support

Early human

LL-37 is the only human cathelicidin antimicrobial peptide, naturally produced by the body's immune cells. Research shows it possesses broad-spectrum antimicrobial properties against bacteria, fungi, and viruses, while also playing a crucial role in immune modulation, reducing inflammation, and accelerating wound healing.

100-250 mcg/day

Vasoactive Intestinal Peptide

Immune Support

Human clinical

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that functions as a potent vasodilator, immune regulator, and neurotransmitter. Research highlights its ability to reduce inflammation, regulate immune responses, and improve respiratory and cardiovascular conditions.

50-100 mcg (nasal spray) or continuous IV infusion in clinical settings

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.